While the role of CIT continues to diminish in frontline CLL, long-term follow-up of patients with mutated IGHV and without tumor protein p53 (TP53) aberrancy treated with FCR in a phase II clinical trial showed sustained progression-free survival (PFS) of 54% at 12 years, with no relapses observed beyond 10.4 years follow-up[2], suggesting FCR could cure a significant portion of patients with good risk disease. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.